Pharmaceutical Executive

By Pharmaceutical Executive PodcastScience Life Sciences

Pharmaceutical Executive episodes

July 13 Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics
In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.
3 min
July 10 Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena
In today's Pharmaceutical Executive Daily, FDA quietly pauses its real-time public release of complete response letters, FDA approves Sanofi's Sarclisa Escena as the first anticancer treatment in the U.S. to be administered via an on-body injector, and AstraZeneca shares fall nearly 10 percent after its Phase III Cardio-TTRansform trial of Wainua in transthyretin-mediated amyloid cardiomyopathy fails to meet its primary endpoint.
4 min
July 09 Pharmaceutical Executive Daily: FDA Approves Ennumo
In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI-enabled precision medicine company Scipher Medicine and Teva's global licensing agreement with Polpharma Biologics, and Alina Chesnokova of Cencora examines how the rise of cold chain-dependent specialty therapies is fundamentally changing how pharmaceutical manufacturers think about commercialization strategy and supply chain partnerships.
5 min
July 08 Pharmaceutical Executive Daily: AI as Reinvention
4 min
July 08 “AI as Reinvention”: Transforming the Business of Medicine
In this episode of the Pharm Exec podcast, Emmanuel Frenehard, executive vice president and chief digital officer at Sanofi, shares how one of the world's largest pharma companies is moving artificial intelligence from proof-of-concept to enterprise scale by embedding AI throughout R&D, manufacturing, commercial operations, and the employee experience. Joining Mike Christel, group managing editor, MJH Life Sciences, Frenehard breaks down Sanofi's three-tiered AI strategy — snackable, specialized, and generative — and explains why the organization views AI as a catalyst for reinvention rather than simply automation.
Frenehard also discusses the governance and cultural changes required to scale responsibly, and outlines how Sanofi's growing AI centers of excellence are helping shape the next generation of pharmaceutical innovation.

36 min
July 07 Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization
3 min
July 01 Pharmaceutical Executive Daily: The Medicare GLP-1 Bridge
In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including Alzheimer's candidate ACD856, the Medicare GLP-1 Bridge launches today, giving eligible Medicare Part D beneficiaries access to Wegovy, Foundayo, and Zepbound for a $50 monthly copay through the end of 2027, and Pharmaceutical Executive speaks with Ryan Last of Troutman Pepper Locke on the limits of targeted pharmaceutical tariffs as a reshoring tool and why thin margins on many generic products complicate the policy's effectiveness.
4 min
June 30 Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program
In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept of healthspan is emerging from academic obscurity into a powerful consumer driver reshaping pharma's role in aging, and Pharmaceutical Executive speaks with Jeff Talbot of Roseman University of Health Sciences on how Las Vegas is positioning itself as an emerging life sciences hub beyond its casino-driven reputation.
4 min
June 29 Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines of therapy in the European Union.
4 min
June 25 Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4 min